Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President, Alzheimer’s Portfolio

Audio By Carbonatix

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 11, 2026--

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive therapies for neurodegenerative diseases, today announced the appointment of Thomas Fagan as Executive Vice President, Alzheimer’s Portfolio, and a member of the company’s Executive Leadership Team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311596883/en/

Thomas Fagan, Executive Vice President, Alzheimer’s Portfolio, Cognito Therapeutics

Mr. Fagan brings more than 25 years of leadership experience across the pharmaceutical, medical device, and diagnostics industries, with deep expertise in Alzheimer’s disease spanning diagnostics, therapeutics, and real-world clinical adoption. He has extensive experience building and aligning cross-functional teams, developing clinical-to-commercial pathways, and working with clinicians, health systems, and payers to accelerate adoption of innovative medical technologies.

In his role at Cognito, Mr. Fagan will lead the company’s Alzheimer’s portfolio, advancing strategic planning and commercial readiness for Spectris™ while helping shape integrated care models that support patients, families, and healthcare providers. His work will focus on aligning clinical development, market preparation, and healthcare system engagement as Cognito progresses toward key clinical milestones, including its pivotal HOPE trial.

“Tom brings deep expertise in Alzheimer’s disease and a proven track record guiding innovative technologies from clinical development to real-world clinical adoption,” said Christian Howell, CEO, Cognito Therapeutics. “As we advance our pivotal HOPE trial and prepare for broader clinical engagement, his leadership will be critical to ensuring we build the infrastructure needed to responsibly and effectively deliver this potential neuroprotective therapy to patients.”

Prior to joining Cognito, Mr. Fagan served as Vice President, U.S. Alzheimer’s Disease Commercial at Eisai Inc., where he led the U.S. commercial strategy for the company’s Alzheimer’s disease portfolio and served on the Executive Committee for the Americas. In this role, he helped guide the launch and market expansion of LEQEMBI® (lecanemab) while building and leading a national commercial organization focused on physician engagement, patient access, and healthcare system readiness.

Prior to Eisai, Mr. Fagan spent nearly a decade at Eli Lilly in leadership roles focused on Alzheimer’s disease. As Global Commercial Leader for Alzheimer’s Disease, he helped design and lead commercialization efforts for Amyvid (florbetapir), the first FDA-approved PET imaging agent used to detect evidence of amyloid plaques associated with Alzheimer’s disease. He also served as Global Brand Development Leader for Alzheimer’s disease programs, where he led commercial strategy for late-stage therapeutic programs and alliances.

“Alzheimer’s disease requires new approaches that bridge scientific innovation with how care is actually delivered to patients and families,” said Mr. Fagan. “Cognito’s work at the intersection of neuroscience, engineering, and patient-centered care represents an exciting opportunity to rethink how we support people living with neurodegenerative disease. I’m thrilled to join the Cognito team at such an important moment as we approach our pivotal study data readout and prepare for potential commercialization next year.”

Mr. Fagan earned his Master of Business Administration (MBA) in general management from Stanford University. He holds a Bachelor of Arts degree in Economics from DePauw University, where he graduated summa cum laude and is a member of Phi Beta Kappa.

About Cognito Therapeutics

Cognito Therapeutics is a late clinical-stage neurotechnology company pioneering neuroprotective therapies to address the unmet needs of patients living with CNS disorders. Its lead product, Spectris™, is an at-home therapeutic platform that uses non-invasive, sensory-driven neurostimulation to evoke coordinated neural activity across interconnected networks. The company’s feasibility studies have shown the potential for Spectris to preserve cognition, daily function, and slow brain atrophy in patients diagnosed with mild-to-moderate AD. Cognito is headquartered in Cambridge, MA. For more information, visit www.cognitotx.com and follow @cognitotx.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260311596883/en/

CONTACT: Media ContactKimberly Ha

KKH Advisors

917-291-5744

[email protected]

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SOFTWARE RESEARCH HARDWARE PHARMACEUTICAL DATA MANAGEMENT CONSUMER TECHNOLOGY MEDICAL DEVICES CLINICAL TRIALS SCIENCE BIOTECHNOLOGY SENIORS HEALTH

SOURCE: Cognito Therapeutics

Copyright Business Wire 2026.

PUB: 03/11/2026 08:00 AM/DISC: 03/11/2026 08:02 AM

http://www.businesswire.com/news/home/20260311596883/en